Fumiko Ladd Chino: Dr. Kekoa Taparra and team evaluated 364 Phase 2/3 trials in 4 top journals
Fumiko Ladd Chino shared on X/Twitter:
“Dr. Kekoa Taparra and team evaluated 364 Phase 2/3 trials in 4 top journals.
- 29% didn’t report race/ethnicity at all.
- For an article that reported, representation of American Indian/Alaska Native and Native Hawaiian OR Other Pacific Islander pts was essentially.
Proud of this work by Dr. Kekoa Taparra done (in part) during his JCO Oncology Practice Editorial Fellowship under the mentoring of Dr. Chirag Shah.
Learn more about the ASCO Journal Fellowships here, applications open Jan 2025.”
Source: Fumiko Ladd Chino/X
Fumiko Ladd Chino is a cancer researcher and Assistant Attending in Radiation Oncology at Memorial Sloan Kettering Cancer Center (USA), who specializes in gynecological and breast cancers. She was also a caregiver for her husband Andrew Mark Ladd, PhD who died from cancer in 2007.
She is a recipient of numerous awards, including ASCO Excellence in Equity Award (2022), Duke Radiation Oncology Award for Outstanding Clinical Research (2019), Duke University Hospital “Good Catch” Award (2018), Conquer Cancer Foundation of ASCO Merit Award (2018), Duke University School of Medicine Dean’s Recognition Award (2014) and Memorial Hermann Hospital, Texas Medical Center Volunteer of the Year Award (2009).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023